NFL Biosciences Logo

NFL Biosciences

ALNFL | PA

Overview

Corporate Details

ISIN(s):
FR0014003XO1 (+1 more)
LEI:
9695006VJWNTN4UNHA27
Country:
France
Address:
199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of substance addictions. The company's lead product, NFL-101, is a patented, nicotine-free treatment for smoking cessation derived from a protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate targeting the reduction of excessive alcohol consumption. NFL Biosciences operates on an R&D-focused model, advancing its drug candidates through preclinical and clinical trials with the strategic goal of licensing them to larger pharmaceutical companies for late-stage development and commercialization.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for NFL Biosciences. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-05-23 07:30
Share Issue/Capital Change
NFL Biosciences announces the success of its capital increase capped at €3 mill…
English 311.5 KB
2025-05-23 07:30
Share Issue/Capital Change
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafo…
French 304.2 KB
2025-05-22 17:45
Share Issue/Capital Change
NFL Biosciences launches a capital increase of approximately €2.2 million
English 354.2 KB
2025-05-22 17:45
Share Issue/Capital Change
NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voi…
French 310.7 KB
2025-05-21 17:45
Post-Annual General Meeting Information
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
French 151.3 KB
2025-05-12 08:30
Board/Management Information
NFL Biosciences strengthens its scientific committee with world-class experts t…
English 177.7 KB
2025-05-12 08:30
Regulatory News Service
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée m…
French 175.8 KB
2025-05-06 18:40
Report Publication Announcement
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et co…
French 151.8 KB
2025-05-05 08:30
Regulatory News Service
NFL Biosciences announces results from a new study conducted with the CEA provi…
English 352.0 KB
2025-05-05 08:30
Earnings Release
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA pe…
French 326.4 KB
2025-04-24 17:45
Regulatory News Service
Marex Group initiates coverage of NFL Biosciences with a Buy rating
English 185.7 KB
2025-04-24 17:45
Regulatory News Service
Marex Group initie à l’achat la couverture de NFL Biosciences
French 164.8 KB
2025-04-15 18:00
Report Publication Announcement
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2…
French 179.3 KB
2025-04-11 17:45
Earnings Release
NFL Biosciences presents its 2024 annual results and provides an update on its…
English 346.5 KB
2025-04-11 17:45
Earnings Release
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son pr…
French 311.1 KB

Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NFL Biosciences via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA